Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048628 | 0.89 | CCR1 (0.44) | TAS1R3TAS1R1TAS1R2CACNA1GSHMT2 | |
| SCHEMBL4052272 | 0.85 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 | |
| SCHEMBL4055124 | 0.83 | EEF2K (0.52) | TAS1R3TAS1R1TAS1R2FAAHALDH1A1 | |
| SCHEMBL4053387 | 0.82 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 | |
| SCHEMBL4057583 | 0.79 | SHMT2 (0.43) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 | |
| SCHEMBL4051629 | 0.77 | ADRA2C (0.48) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 | |
| SCHEMBL13904933 | 0.77 | CCR1 (0.46) | TAS1R3TAS1R1TAS1R2SHMT2CCR1 | |
| SCHEMBL4046956 | 0.75 | ADRA2C (0.46) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 | |
| SCHEMBL4055918 | 0.75 | EPHX2 (0.43) | TAS1R3TAS1R1TAS1R2SHMT2MEN1 | |
| SCHEMBL4052023 | 0.74 | RAB9A (0.41) | TAS1R3TAS1R1TAS1R2SHMT2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | TAS1R3 3386/4885TAS1R1 3390/4885TAS1R2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.